English name: apremilast
Product name: Otezla
Formulation and specifications: tablets, 10mg, 20mg, 30mg.
Manufacturer: Celgene (Searle gene)
Apremilast (Otezla) was approved by FDA on March 38, 2004+March 2004 for the treatment of psoriatic arthritis. According to the industry, despite the competition from tumor necrosis factor (TNF) inhibitors, especially Humira (adalimumab) from Abbey and Entrel (Etanercep) from Pfizer/Amgen. However, Otezla is an oral drug without routine laboratory monitoring. Compared with commercially available drugs, Ozra has great advantages and will provide important treatment options for patients and doctors.
20 14 was approved by the US Food and Drug Administration (FDA) on September 23rd for the treatment of moderate and severe plaque psoriasis suitable for phototherapy and systemic treatment.